Lower levels of tristetraprolin in human prostate cancer prostatectomy tissue are associated with more aggressive prostate cancer and may serve as an actionable prognostic and predictive biomarker.
Finally, pooled survival analysis suggests that <i>TTP</i> RNA expression provides independent information beyond CAPRA-S to predict BCR.<b>Conclusions:</b> TTP is a promising prostate cancer biomarker for predicting which RP patients will have poor outcomes, especially for low-grade prostate cancer patients.<b>Impact:</b> This study suggests that <i>TTP</i> RNA expression can be used to enhance the accuracy of CAPRA-S to predict outcomes in patients treated with RP.
A newly predicted interaction between NEDD9 and ZFP36 in particular was validated by co-immunoprecipitation, as was NEDD9's potential biological role in prostate cancer cell growth regulation.
Collectively, these findings suggest that TTP is an important prognostic indicator for prostate cancer, and augmenting TTP function would effectively disable the metabolism and proliferation of aggressive prostate tumors.